MX365612B - Polipeptidos de factor x modificados y usos de los mismos. - Google Patents

Polipeptidos de factor x modificados y usos de los mismos.

Info

Publication number
MX365612B
MX365612B MX2015001083A MX2015001083A MX365612B MX 365612 B MX365612 B MX 365612B MX 2015001083 A MX2015001083 A MX 2015001083A MX 2015001083 A MX2015001083 A MX 2015001083A MX 365612 B MX365612 B MX 365612B
Authority
MX
Mexico
Prior art keywords
polypeptides
factor
modified factor
modified
zymogen
Prior art date
Application number
MX2015001083A
Other languages
English (en)
Other versions
MX2015001083A (es
Inventor
Thanos Christopher
L Madison Edwin
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of MX2015001083A publication Critical patent/MX2015001083A/es
Publication of MX365612B publication Critical patent/MX365612B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporcionan proteínas terapéuticas modificadas. En particular se proporcionan polipéptidos de factor X modificado, que incluyen el zimógeno de Factor X, Factor Xa y otras formas de Factor X y uso de los mismos.
MX2015001083A 2012-07-25 2013-03-15 Polipeptidos de factor x modificados y usos de los mismos. MX365612B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261741806P 2012-07-25 2012-07-25
PCT/US2013/032616 WO2014018120A1 (en) 2012-07-25 2013-03-15 Modified factor x polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
MX2015001083A MX2015001083A (es) 2015-04-08
MX365612B true MX365612B (es) 2019-06-07

Family

ID=48040462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001083A MX365612B (es) 2012-07-25 2013-03-15 Polipeptidos de factor x modificados y usos de los mismos.

Country Status (18)

Country Link
US (2) US9145552B2 (es)
EP (1) EP2877487B1 (es)
JP (2) JP6363600B2 (es)
KR (1) KR102049900B1 (es)
CN (1) CN104755492A (es)
AU (1) AU2013293573B2 (es)
BR (1) BR112015001628A2 (es)
CA (1) CA2879785C (es)
EA (1) EA028865B1 (es)
ES (1) ES2704083T3 (es)
HK (1) HK1210790A1 (es)
IL (1) IL236449B (es)
IN (1) IN2015DN01404A (es)
MX (1) MX365612B (es)
NZ (1) NZ703148A (es)
SG (1) SG11201500579SA (es)
WO (1) WO2014018120A1 (es)
ZA (1) ZA201500097B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5629423B2 (ja) 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
KR20150033726A (ko) 2006-07-05 2015-04-01 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
KR20100016462A (ko) * 2007-04-13 2010-02-12 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
IN2015DN01404A (es) 2012-07-25 2015-07-03 Catalyst Biosciences Inc
WO2015044836A1 (en) 2013-09-24 2015-04-02 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
ES2772802T3 (es) * 2014-01-24 2020-07-08 Pfizer Composiciones y procedimientos para tratar la hemorragia intracerebral
US10444715B2 (en) * 2014-05-01 2019-10-15 Belkin International, Inc. Controlling settings and attributes related to operation of devices in a network
EP3149163B1 (en) * 2014-05-26 2020-06-03 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
WO2016110510A1 (en) * 2015-01-07 2016-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated factor x polypeptides and uses thereof for the treatment of haemophilia
WO2017017109A1 (en) * 2015-07-27 2017-02-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated factor x polypeptides and uses thereof for the treatment of haemophilia
AU2017205364B2 (en) * 2016-01-07 2021-03-04 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions
FR3050992A1 (fr) * 2016-05-06 2017-11-10 Lab Francais Du Fractionnement Mutants du facteur x
FR3077296A1 (fr) * 2018-02-01 2019-08-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Dimeres de variants du facteur x
WO2019201868A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Coagulation factor based fusion protein with half-life extending polypeptide
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP3831843A1 (en) * 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland A hemostatic agent and uses thereof
US20230190679A1 (en) * 2021-11-09 2023-06-22 YewSavin, Inc. Compositions and methods for treating bleeding and bleeding disorders
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116426510B (zh) * 2023-06-13 2023-09-22 北京沃森赛瑟生物技术有限公司 含修饰Xa因子的利伐沙班检测试剂盒及检测方法与应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AU6673898A (en) 1997-03-07 1998-09-22 Washington University Factor x variant
US20030207402A1 (en) 1997-08-22 2003-11-06 Erhard Kopetzki Autocatalytically activatable zymogenic precursors of proteases and their use
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
US20030186329A1 (en) 1999-03-22 2003-10-02 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2002230390A1 (en) 2000-10-05 2002-04-29 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
CA2447023A1 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2002315525A1 (en) 2001-07-03 2003-01-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US20030143219A1 (en) 2001-10-09 2003-07-31 Madison Edwin L Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
WO2003044179A2 (en) 2001-11-20 2003-05-30 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003247776A1 (en) 2002-07-02 2004-01-23 Dendreon Corporation Serine protease 16
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
NZ590187A (en) 2002-10-02 2012-07-27 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
WO2005022330A2 (en) 2003-08-27 2005-03-10 Jambo Networks, Inc. A system and method for providing communication services to mobile device users
WO2005023308A1 (en) 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
DE10350880A1 (de) 2003-10-31 2005-06-02 Roche Diagnostics Gmbh Verfahren zur Bestimmung eines Analyten mittels einer Extraktionsschicht
JP5629423B2 (ja) 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
WO2005123119A2 (en) 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration of neutral endopeptidase to treat inflammatory bowel disease
JP2008532544A (ja) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
EP1726643A1 (en) 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
KR20150033726A (ko) 2006-07-05 2015-04-01 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
KR20100016462A (ko) 2007-04-13 2010-02-12 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
DK3078743T3 (da) * 2007-09-28 2020-08-10 Portola Pharm Inc Antidoter til faktor xa-inhibitorer og fremgangsmåder til anvendelse af disse
DK2436765T3 (da) 2007-10-09 2014-01-13 Chemo Sero Therapeut Res Inst Rekombinant faktor X uden glycosylering og fremgangsmåde til fremstilling deraf
CN102014948A (zh) 2008-02-07 2011-04-13 安德鲁·贝克 腺病毒向性的调节
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
US20110137011A1 (en) * 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
EP2358874B1 (en) 2008-12-19 2017-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
EP3604510A1 (en) 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
PT2453910T (pt) 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP6514893B2 (ja) 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
IN2015DN01404A (es) 2012-07-25 2015-07-03 Catalyst Biosciences Inc

Also Published As

Publication number Publication date
CN104755492A (zh) 2015-07-01
MX2015001083A (es) 2015-04-08
CA2879785C (en) 2019-06-18
JP2018183147A (ja) 2018-11-22
US20140234290A1 (en) 2014-08-21
JP6363600B2 (ja) 2018-07-25
EA201500172A1 (ru) 2015-09-30
WO2014018120A1 (en) 2014-01-30
US9145552B2 (en) 2015-09-29
KR102049900B1 (ko) 2019-11-28
US20140030247A1 (en) 2014-01-30
JP2015524801A (ja) 2015-08-27
AU2013293573A1 (en) 2015-02-05
ES2704083T3 (es) 2019-03-14
BR112015001628A2 (pt) 2017-11-07
HK1210790A1 (en) 2016-05-06
SG11201500579SA (en) 2015-02-27
EP2877487B1 (en) 2018-10-17
US9856467B2 (en) 2018-01-02
IL236449A0 (en) 2015-02-26
EP2877487A1 (en) 2015-06-03
KR20160073937A (ko) 2016-06-27
CA2879785A1 (en) 2014-01-30
ZA201500097B (en) 2016-09-28
AU2013293573B2 (en) 2016-10-27
IL236449B (en) 2019-02-28
EA028865B1 (ru) 2018-01-31
IN2015DN01404A (es) 2015-07-03
NZ703148A (en) 2016-08-26

Similar Documents

Publication Publication Date Title
MX365612B (es) Polipeptidos de factor x modificados y usos de los mismos.
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
EP4223770A3 (en) Novel fusion molecules and uses thereof
MY162837A (en) Modified relaxin polypeptides and their uses
AU345145S (en) Bottle
AU335765S (en) Tile spacer
UY34254A (es) Proteínas y péptidos modificados.
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
AU343235S (en) Bottle
UA110103C2 (uk) Модифікований туберкульозний антиген
AU339376S (en) Sterilizing case
AU344326S (en) Bottle
AU347955S (en) Audio system
AU337524S (en) Bottle
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX365403B (es) Peptidos y metodos para usarlos.
AU345141S (en) Bottle
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
AU343226S (en) Bottle
AU345245S (en) Muffler
AU339266S (en) Chair
AU338124S (en) Remote control
TN2013000056A1 (en) Modified relaxin polypeptides and their uses
AU334592S (en) Tile spacer spindle
WO2014169254A3 (en) Therapeutic peptide-expressing cells

Legal Events

Date Code Title Description
FG Grant or registration